Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax

• Authors: David M. Bell, Emory University; Phyllis E Kozarsky, Emory University; David S Stephens, Emory University
• Journal Title: Emerging Infectious Disease
• Volume: Volume 8, Number 2
• Publisher: Centers for Disease Control and Prevention | 2002-03-19, Pages 222-225
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.3201/eid0802.010521
• Subjects: Health Sciences, Public Health; Health Sciences, Medicine and Surgery
• Keywords: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Centers for Disease Control and Prevention (U.S.); Ciprofloxacin; Diagnosis, Differential; Doxycycline; Humans; Penicillin G Procaine; United States

Abstract

On November 18, 2001, a meeting was held at the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, to discuss the prophylaxis, diagnosis, and treatment of anthrax. Participants included clinicians and health department personnel from areas where anthrax cases were identified, infectious disease experts, representatives of professional societies, and experts from federal agencies. A patient recovering from inhalational anthrax also described her illness. The following is a summary of the presentations and discussion.